CN111000106A - Composite probiotic solid beverage - Google Patents
Composite probiotic solid beverage Download PDFInfo
- Publication number
- CN111000106A CN111000106A CN201911387488.7A CN201911387488A CN111000106A CN 111000106 A CN111000106 A CN 111000106A CN 201911387488 A CN201911387488 A CN 201911387488A CN 111000106 A CN111000106 A CN 111000106A
- Authority
- CN
- China
- Prior art keywords
- composite
- probiotics
- oligosaccharide
- solid beverage
- probiotic solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 45
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 45
- 239000002131 composite material Substances 0.000 title claims abstract description 37
- 235000013361 beverage Nutrition 0.000 title claims abstract description 19
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 16
- 239000007787 solid Substances 0.000 title claims abstract description 16
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 21
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 21
- 239000011782 vitamin Substances 0.000 claims abstract description 17
- 235000013343 vitamin Nutrition 0.000 claims abstract description 17
- 229940088594 vitamin Drugs 0.000 claims abstract description 17
- 229930003231 vitamin Natural products 0.000 claims abstract description 17
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 12
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 11
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000010447 xylitol Nutrition 0.000 claims abstract description 10
- 239000000811 xylitol Substances 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 10
- 229960002675 xylitol Drugs 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 235000013336 milk Nutrition 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 20
- 239000000126 substance Substances 0.000 abstract description 10
- 239000003755 preservative agent Substances 0.000 abstract description 9
- 235000013325 dietary fiber Nutrition 0.000 abstract description 8
- 230000036449 good health Effects 0.000 abstract description 3
- 241000282414 Homo sapiens Species 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 239000003765 sweetening agent Substances 0.000 description 10
- 235000003599 food sweetener Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- -1 compound vitamin Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/42—Preservation of non-alcoholic beverages
- A23L2/44—Preservation of non-alcoholic beverages by adding preservatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a composite probiotic solid beverage which is prepared from the following powdery raw materials in percentage by weight: 0.6-0.8% of composite probiotics, 0.2-0.4% of composite vitamins, 7-11% of chitosan oligosaccharide, 24-26% of xylo-oligosaccharide and 62-68% of xylitol; the probiotics comprise bifidobacterium lactis and lactobacillus rhamnosus according to the weight ratio of 3-5: 1. The invention has good taste, combines the optimized probiotics, the water-soluble dietary fiber and the vitamins, greatly improves the efficacy of the components, enhances the effect by multiple times compared with the effect achieved by singly adopting a single component, has good health care efficacy and does not contain chemical preservatives; the carrying is convenient; is suitable for wide crowd and diabetics.
Description
Technical Field
The invention relates to the technical field of drinks, and particularly relates to a composite probiotic solid beverage.
Background
Hundreds of millions of bacteria inhabit in intestinal tracts and body surfaces of human bodies, the types of the bacteria are more than 400, the weight of the bacteria is two kilograms, the bacteria are harmful to human bodies, are called harmful bacteria and beneficial to human bodies, are called probiotics, and have conditional pathogenic bacteria between the bacteria, namely the bacteria which can cause the human bodies to be sick under certain conditions, and the probiotics in the human bodies mainly comprise lactic acid bacteria, bifidobacterium lactis and the like.
Scientific research proves that massive propagation of probiotics in intestinal tracts can treat pseudomembranous enteritis caused by massive use of antibiotics; treating constipation and chronic diarrhea; protecting the liver; preventing and treating hypertension and arteriosclerosis, resisting aging, reducing serum cholesterol, preventing cancer, and inhibiting tumor growth.
Water soluble dietary fibers are a type of fiber that is soluble in water. Has viscosity, and can absorb a large amount of water in intestinal tract to keep feces in soft state. The water-soluble fiber can effectively activate beneficial bacteria in the intestinal tract, promote mass propagation of beneficial bacteria and create healthy ecology of the intestinal tract.
At present, the beverages on the market are various, essence, sweetener and the like are mostly added for researching the taste, the additives contain a large amount of saturated fatty acid and trans-fatty acid, the nutritional value is low, the human body can be injured after long-term drinking, and the beverage combining probiotics, water-soluble dietary fiber and vitamins is not available.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide the composite probiotic solid beverage which has good taste, combines the optimized probiotics, the water-soluble dietary fiber and the vitamins, greatly improves the efficacy of the components, enhances the effect by multiple times compared with the effect achieved by singly adopting a single component, has good health care efficacy, no chemical preservative, low product storage and transportation requirements and long quality guarantee period; is convenient to carry and can be drunk or eaten at any time; is suitable for wide crowd and diabetics.
The purpose of the invention is realized by the following technical scheme: the composite probiotic solid beverage is prepared from the following powdery raw materials in percentage by weight: 0.6-0.8% of composite probiotics, 0.2-0.4% of composite vitamins, 7-11% of chitosan oligosaccharide, 24-26% of xylo-oligosaccharide and 62-68% of xylitol; the probiotics comprise bifidobacterium lactis and lactobacillus rhamnosus according to the weight ratio of 3-5: 1.
Preferably, the composite probiotic solid beverage is prepared from the following powdery raw materials in percentage by weight: 0.7% of composite probiotics, 0.3% of composite vitamins, 9% of chitosan oligosaccharide, 25% of xylo-oligosaccharide and 65% of xylitol; the composite probiotics comprise bifidobacterium lactis and lactobacillus rhamnosus according to the weight ratio of 4: 1.
Preferably, the composite probiotic solid beverage can be directly eaten or uniformly drunk by stirring with a solution, and the temperature of the solution is not higher than 37 ℃.
Preferably, the solution may be water, milk or soy milk.
Bifidobacterium lactis: bifidobacterium lactis is a health sign of a human body and is a beneficial flora which has a plurality of benefits to the human body. The Bifidobacterium lactis appears in infants 3-4 months after birth, the number of the Bifidobacterium lactis gradually increases and reaches the peak in the infant period, the Bifidobacterium lactis accounts for about 25% of the total amount of intestinal bacteria, the number of the Bifidobacterium lactis decreases year by year with the increase of age, and the number of the Bifidobacterium lactis decreases to below 7.9% in the elderly period. Modern studies have shown that by administering bifidobacterium lactis, the proportion of total, helper and activating T cells in the peripheral circulation can be increased, and the number of immune cells can be effectively increased to improve physical fitness. Bifidobacterium lactis can enhance cellular immune function, phagocytosis of leukocytes and kill tumor cells. Has very good effect on individuals with weak immune intervention function, and also has the following functions: preventing and treating constipation, reducing weight, preventing colon and rectal cancer, preventing and treating hemorrhoid, reducing blood lipid, improving diabetes symptom, improving oral cavity and teeth function, preventing and treating cholelithiasis, and preventing female breast cancer.
Lactobacillus rhamnosus: the lactobacillus rhamnosus is 1 strain of lactobacillus separated from intestinal tracts of healthy people, is one of the most widely studied probiotics for human beings, belongs to third-generation probiotics, can resist the environment of digestive tracts of animals, is planted in intestinal tracts of people and animals, has the effects of regulating intestinal flora, preventing and treating diarrhea, removing toxins, improving body immunity and the like, and has a good relieving effect on allergic constitution.
The xylo-oligosaccharide belongs to water-soluble dietary fiber, is also called xylo-oligosaccharide, is a functional polysaccharide formed by combining 2-7 xylose molecules by β -1, 4 glycosidic bonds, has unique advantages compared with soybean oligosaccharide, fructo-oligosaccharide, isomaltooligosaccharide and the like used by people, and can selectively promote the proliferation activity of bifidobacterium lactis in intestinal tracts.
Chitosan oligosaccharide: the chitosan is degraded by a special biological enzyme technology (reports of using chemical degradation and microwave degradation technologies) to obtain an oligosaccharide product with the polymerization degree of 2-20, the molecular weight of less than or equal to 3200Da, and the oligosaccharide product is a low-molecular-weight product with good water solubility, large functional effect and high biological activity. It has several unique functions of high solubility, complete water solubility, easy absorption and utilization by organism, etc. and its action is 14 times that of chitosan. It has: low molecular weight, good water solubility, large functional action, easy absorption by human body, high biological activity and the like, and simultaneously has the following advantages: the natural preservative has the characteristics of pure nature, no radiation, no pollution, no addition and the like, is used as an activating factor of probiotics, enhances the absorption of calcium and mineral substances, and is also used as a natural preservative product to replace sodium benzoate and other chemical preservatives.
Xylitol: the sweetening agent is an intermediate of human carbohydrate metabolism, under the condition that the carbohydrate metabolism is influenced by lack of insulin in vivo, the sweetening agent does not need insulin to promote, xylitol can also permeate cell membranes to be absorbed and utilized by tissues, the synthesis of glycogen is promoted, the nutrition and energy are supplied to cells, the increase of blood sugar value is not caused, the symptoms of polyphagia, polydipsia and diuresis after being taken by diabetes patients are eliminated, the sweetening agent is a nutritional sugar substitute which is most suitable for the diabetes patients to eat, the synthesis of glycogen is promoted, the blood sugar cannot rise, the sweetening agent has the effects of improving liver functions and resisting fatty liver for liver disease patients, the sweetening agent is an ideal auxiliary medicine for treating persistent hepatitis B, chronic hepatitis B and liver cirrhosis, the sweetening agent is an ideal auxiliary medicine for hepatitis complications patients, and the sweetening agent has the effects of preventing decayed teeth and losing.
Vitamin complex: vitamins and trace elements are important substances necessary for maintaining normal life activities of the human body. Deficiency can lead to metabolic disorders, causing a variety of diseases. The vitamin medicine constitutes multiple coenzymes, participates in metabolism, utilization and synthesis of multiple substances, promotes bone growth, maintains structural integrity of epithelial tissues, and keeps normal growth and development. Important physiological functions of trace elements are: participating in the constitution and activation of enzymes; constitute important carriers and electron transfer systems in vivo.
The invention has the beneficial effects that:
(1) the mouthfeel is good;
(2) the milk bifidobacterium powder, the lactobacillus rhamnosus, the xylo-oligosaccharide, the chitosan oligosaccharide and the compound vitamin are blended for many times to finally obtain the compatibility of each component, the efficacy of the components is greatly improved, and the effect is enhanced by many times compared with the effect achieved by only adopting a single component; this is an important breakthrough and effect that is difficult to imagine at the beginning of the production or normally: xylo-oligosaccharide is not only dietary fiber and a sweetening agent, but also can directly enter the large intestine and be preferentially utilized by bifidobacterium lactis, thereby promoting the proliferation of bifidobacterium lactis and simultaneously generating a plurality of organic acids, reducing the pH value of the intestinal tract, inhibiting the growth of harmful bacteria, leading probiotics to proliferate in the intestinal tract in large quantity and greatly enhancing the efficacy of the probiotics, and chitosan oligosaccharide is not only dietary fiber but also an activating factor of the probiotics; meanwhile, the compound vitamin is preferably added, so that the health care and immunity improvement effects on the heart and brain of the human body are greatly enhanced;
(3) the matching proportion of each component is balanced and reasonable, the functions of each component are effectively exerted, the components interact and promote the absorption of the human body, and the formula has the following advantages: the traditional Chinese medicine composition has the effects of enhancing the cellular immune function, phagocytosis of leukocytes, killing tumor cells, regulating intestinal flora, preventing and treating diarrhea, removing toxins, improving the immunity of organisms and the like, has a good relieving effect on allergic constitution, strengthens the immunocompetence of cells, induces diuresis to reduce swelling, prevents and treats tumors, and reduces cardiovascular and cerebrovascular diseases;
(4) the chitosan oligosaccharide does not contain artificial chemical preservatives, the chitosan oligosaccharide not only enhances the absorption of calcium and mineral substances, but also can be used as a natural preservative product to replace sodium benzoate and other chemical preservatives, the product storage and transportation requirements are low, and the quality guarantee period is long;
(5) is convenient to carry and can be drunk or eaten at any time;
(6) is suitable for wide crowd and diabetics.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1:
the composite probiotic solid beverage is prepared from the following powdery raw materials in percentage by weight: 0.6% of composite probiotics, 0.4% of composite vitamins, 7% of chitosan oligosaccharide, 24% of xylo-oligosaccharide and 68% of xylitol; the composite probiotics comprise bifidobacterium lactis and lactobacillus rhamnosus according to the weight ratio of 3: 1. The beverage can be directly eaten or uniformly drunk by stirring with water, and the temperature of the water is not higher than 37 ℃.
Example 2:
the composite probiotic solid beverage is prepared from the following powdery raw materials in percentage by weight: 0.8% of composite probiotics, 0.2% of composite vitamins, 11% of chitosan oligosaccharide, 26% of xylo-oligosaccharide and 62% of xylitol; the composite probiotics consists of bifidobacterium lactis and lactobacillus rhamnosus according to the weight ratio of 5: 1, can be directly eaten or uniformly stirred by milk for drinking, and the temperature of the milk is not higher than 37 ℃.
Example 3:
the composite probiotic solid beverage is prepared from the following powdery raw materials in percentage by weight: 0.7% of composite probiotics, 0.3% of composite vitamins, 9% of chitosan oligosaccharide, 25% of xylo-oligosaccharide and 65% of xylitol; the composite probiotics comprise bifidobacterium lactis and lactobacillus rhamnosus according to the weight ratio of 4: 1. Can be directly eaten or uniformly stirred with soybean milk for drinking, wherein the temperature of the soybean milk is not higher than 37 ℃.
The invention has good taste, combines the optimized probiotics, the water-soluble dietary fiber and the vitamins, greatly improves the efficacy of the components, enhances the effect by multiple times compared with the effect achieved by singly adopting a single component, has good health care efficacy, no chemical preservative, low requirement on storage and transportation of the product and long shelf life; is convenient to carry and can be drunk or eaten at any time; is suitable for wide crowd and diabetics.
The above-mentioned embodiments only express the specific embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention.
Claims (4)
1. The composite probiotic solid beverage is characterized by being prepared from the following powdery raw materials in percentage by weight: 0.6-0.8% of composite probiotics, 0.2-0.4% of composite vitamins, 7-11% of chitosan oligosaccharide, 24-26% of xylo-oligosaccharide and 62-68% of xylitol; the probiotics comprise bifidobacterium lactis and lactobacillus rhamnosus according to the weight ratio of 3-5: 1.
2. The composite probiotic solid beverage according to claim 1, which is prepared from the following powdery raw materials in percentage by weight: 0.7% of composite probiotics, 0.3% of composite vitamins, 9% of chitosan oligosaccharide, 25% of xylo-oligosaccharide and 65% of xylitol; the composite probiotics comprise bifidobacterium lactis and lactobacillus rhamnosus according to the weight ratio of 4: 1.
3. The composite probiotic solid beverage is characterized in that the composite probiotic solid beverage can be directly eaten or uniformly drunk by stirring a solution, and the temperature of the solution is not higher than 37 ℃.
4. The composite probiotic solid beverage according to claim 3, characterized in that the solution can be water, milk or soybean milk.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911387488.7A CN111000106A (en) | 2019-12-27 | 2019-12-27 | Composite probiotic solid beverage |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911387488.7A CN111000106A (en) | 2019-12-27 | 2019-12-27 | Composite probiotic solid beverage |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111000106A true CN111000106A (en) | 2020-04-14 |
Family
ID=70118160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911387488.7A Pending CN111000106A (en) | 2019-12-27 | 2019-12-27 | Composite probiotic solid beverage |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111000106A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114271505A (en) * | 2021-11-19 | 2022-04-05 | 中国药科大学 | Additive for promoting proliferation of lactobacillus rhamnosus, preparation method and application |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106617091A (en) * | 2016-11-08 | 2017-05-10 | 广东正当年生物科技有限公司 | Probiotics and prebiotic compound preparation |
CN107594284A (en) * | 2017-10-23 | 2018-01-19 | 南京邦康生物技术有限公司 | A kind of solid beverage containing prebiotics and probiotics and preparation method thereof |
CN108041169A (en) * | 2017-11-29 | 2018-05-18 | 上海晨冠乳业有限公司 | A kind of children's solid beverage containing probiotics and prebiotics and preparation method thereof |
CN108142928A (en) * | 2017-12-25 | 2018-06-12 | 北京数果科技有限公司 | For the compound probiotic composition of intestinal canal regulating and its application |
CN108295098A (en) * | 2018-02-02 | 2018-07-20 | 云南中京国建投资有限公司 | The symphysis unit composition and its preparation of a kind of auxiliary hyperglycemic and application |
CN109288063A (en) * | 2018-09-14 | 2019-02-01 | 安吉艾格赛思生物科技有限公司 | A kind of multi-joint Cernevit-12 and preparation method thereof being proliferated beneficial bacteria of intestinal tract |
CN110179123A (en) * | 2019-05-25 | 2019-08-30 | 管国帅 | The comprehensive compound freeze-dried powder of probiotics |
-
2019
- 2019-12-27 CN CN201911387488.7A patent/CN111000106A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106617091A (en) * | 2016-11-08 | 2017-05-10 | 广东正当年生物科技有限公司 | Probiotics and prebiotic compound preparation |
CN107594284A (en) * | 2017-10-23 | 2018-01-19 | 南京邦康生物技术有限公司 | A kind of solid beverage containing prebiotics and probiotics and preparation method thereof |
CN108041169A (en) * | 2017-11-29 | 2018-05-18 | 上海晨冠乳业有限公司 | A kind of children's solid beverage containing probiotics and prebiotics and preparation method thereof |
CN108142928A (en) * | 2017-12-25 | 2018-06-12 | 北京数果科技有限公司 | For the compound probiotic composition of intestinal canal regulating and its application |
CN108295098A (en) * | 2018-02-02 | 2018-07-20 | 云南中京国建投资有限公司 | The symphysis unit composition and its preparation of a kind of auxiliary hyperglycemic and application |
CN109288063A (en) * | 2018-09-14 | 2019-02-01 | 安吉艾格赛思生物科技有限公司 | A kind of multi-joint Cernevit-12 and preparation method thereof being proliferated beneficial bacteria of intestinal tract |
CN110179123A (en) * | 2019-05-25 | 2019-08-30 | 管国帅 | The comprehensive compound freeze-dried powder of probiotics |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114271505A (en) * | 2021-11-19 | 2022-04-05 | 中国药科大学 | Additive for promoting proliferation of lactobacillus rhamnosus, preparation method and application |
CN114271505B (en) * | 2021-11-19 | 2023-05-23 | 中国药科大学 | Additive for promoting multiplication of lactobacillus rhamnosus, preparation method and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2216611T3 (en) | PREPARATION CONTAINING OLIGOSACARIDS AND PROBIOTICS. | |
US6203797B1 (en) | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome | |
CN101606704B (en) | Dietary fiber food with various functional actions | |
CN109198356A (en) | A kind of solid beverage and preparation method thereof with adjusting function of intestinal canal | |
CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
CN100542430C (en) | A kind of nutrition albumen powder that contains profitable probliotics | |
WO2022016774A1 (en) | Composition beneficial for regulating intestinal tract, promoting digestion and improving constipation, and preparation method therefor | |
CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
CN111227261A (en) | Prebiotic composition and application thereof | |
CN105146368A (en) | Nutritional package for relieving malnutrition and helping after-illness and post-operation physical rehabilitation | |
CN104839683A (en) | Medical formula food for people with constipation | |
CN108968037A (en) | Senile dementia full nutrition formula food | |
KR100716123B1 (en) | Food composition comprising fermented dioscorea batatas decne. and the rhizoma thereof with lactic acid for preventing and improving constipation and obesity | |
CN105029393A (en) | Medical formula food for children | |
CN102742653B (en) | Brain-strengthening and nerve soothing probiotic goat milk tablet and preparation method of brain-strengthening and nerve soothing probiotic goat milk tablet | |
CN114271502A (en) | Clam peptide compound for protecting cardiovascular system and kidney and application thereof | |
CN111543605A (en) | Comprehensive nutrition powder for people with hypertension, hyperlipidemia and obesity | |
CN115736142A (en) | Formula and preparation process of prebiotics prune fiber fruit drink | |
CN114794347A (en) | Seaweed solid beverage | |
CN104187643A (en) | All-nutrition formula food for yang-deficiency constitution | |
CN107467193B (en) | A powder food based on goat milk for special medical use and its preparation method | |
CN105707378A (en) | Black-highland barley coffee with effect of slimming | |
CN111000106A (en) | Composite probiotic solid beverage | |
CN112167639A (en) | Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof | |
CN102187964A (en) | Instant coarse grain porridge for treating constipation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Liu Jun Document name: Notice of deemed withdrawal |
|
DD01 | Delivery of document by public notice | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200414 |
|
WD01 | Invention patent application deemed withdrawn after publication |